Semaglutide is perfectly tolerated without threat of hypoglycaemia in monotherapy but suffers from gastrointestinal adverse effects. A substantial population afflicted with COVID-19 infection have been diabetic; consequently usage of semaglutide in diabetic issues and also CV patients might be very